Your position:
m.limatoxi.com
>>
EN
>>
Pharmaceutical News
>>
Industry
>>
Irassa certified as frontier NSCLC drug
>> article
Irassa certified as frontier NSCLC drug
Editor:lizz Clicks:
0
Date:2010-12-27 16:39:22
Keyword:
lung cancer NSCLC Gefitinib Iressa
Healthoo Information:
AstraZeneca's Iressa become first-line treatment for NSCLC patients in China.
UserLogin
UserName：
Password：
The non-formal user may read the summary, the formal user can read the whole article。
please at once register the user of Heatlhoo.com
After registration, we will provide the sample reports and the more comprehensive consulting services for you.
UserName
Contact:
Title:
Mr.
Ms.
Password
Repeat password:
Mobile
Email
Verification code:
Company Name
E-mail:xuezhe@healthoo.com
Tel.:86-10-68032463
Our services:
China Im\Ex data service
Service fees of Chinese Vision
Our service items
Online information introduction
Monthly information
Relative Information
CFDA warns of online sales of fake ...
Cervical cancer increases among young Chinese...
3 expensive anticancer drugs into medicare&nb...
China encourages private investment for cance...
Sales growth trend of anticancer drugs i...
Cancer on the rise in China
Breast cancer to be top cancer for ...
Conmana (Icotinib) injection launched in Chin...
Top 20 anticancer drugs in sample hospit...
Top 10 companies of anticancer drugs in&...
Address: 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
Tel:+86-10-68032463
map
